12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SYL040012: Phase IIa data

A double-blind, dose-ranging, European Phase IIa trial in 80 patients with ocular hypertension or open-angle glaucoma showed that once-daily 300 µg SLY040012 eye drops for 14 days met the...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >